These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34995105)

  • 1. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
    Mayer EL; Fesl C; Hlauschek D; Garcia-Estevez L; Burstein HJ; Zdenkowski N; Wette V; Miller KD; Balic M; Mayer IA; Cameron D; Winer EP; Ponce Lorenzo JJ; Lake D; Pristauz-Telsnigg G; Haddad TC; Shepherd L; Iwata H; Goetz M; Cardoso F; Traina TA; Sabanathan D; Breitenstein U; Ackerl K; Metzger Filho O; Zehetner K; Solomon K; El-Abed S; Theall KP; Lu DR; Dueck A; Gnant M; DeMichele A
    J Clin Oncol; 2022 Feb; 40(5):449-458. PubMed ID: 34995105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL;
    J Clin Oncol; 2022 Jan; 40(3):282-293. PubMed ID: 34874182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
    Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
    Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
    Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
    Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
    Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
    N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
    Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
    Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
    Marmé F; Martin M; Untch M; Thode C; Bonnefoi H; Kim SB; Bear H; Mc Carthy N; Gelmon K; García-Sáenz JA; Kelly CM; Reimer T; Valota O; Toi M; Rugo HS; Gnant M; Makris A; Bassy M; Zhang Z; Furlanetto J; Nekljudova V; Loibl S
    ESMO Open; 2024 Jun; 9(6):103466. PubMed ID: 38838498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
    Loibl S; Marmé F; Martin M; Untch M; Bonnefoi H; Kim SB; Bear H; McCarthy N; Melé Olivé M; Gelmon K; García-Sáenz J; Kelly CM; Reimer T; Toi M; Rugo HS; Denkert C; Gnant M; Makris A; Koehler M; Huang-Bartelett C; Lechuga Frean MJ; Colleoni M; Werutsky G; Seiler S; Burchardi N; Nekljudova V; von Minckwitz G
    J Clin Oncol; 2021 May; 39(14):1518-1530. PubMed ID: 33793299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
    Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
    Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
    Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
    J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Freedman RA; Tolaney SM
    Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
    Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
    Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
    Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
    Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    DeMichele A; Cristofanilli M; Brufsky A; Liu X; Mardekian J; McRoy L; Layman RM; Emir B; Torres MA; Rugo HS; Finn RS
    Breast Cancer Res; 2021 Mar; 23(1):37. PubMed ID: 33761995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.